Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and b...

Autores: Vignaduzzo, Silvana Edit; Castellano, Patricia Margarita; Kaufman, Teodoro Saul
Año de publicación: 2011
Idioma: inglés
Tipo de recurso: artículo
Estado: versión publicada
Descripción: The novel triple combination between Amlodipine (AML), Hydrochlorothiazide (HCT), and Valsartan (VAL) provides a new option for treating hypertension. The development and validation of an HPLC method for their simultaneous determination in pharmaceutical combinations, employing experimental design strategies, is reported. The drugs were separated on a C18 column at 30° C, using a 38:62 (v/v) mixture of 30 mMphosphate buffer (pH 5.5) and MeOH as mobile phase, delivered at 1.0mLmin -1. Detection was performed at 234 nm. Despite the wide difference in analytes' concentrations, the method showed good linearity (r 2 > 0.995) in the ranges 7.0-13.0 μg mL -1, 17.6-32.8 μg mL -1, and 226.2-420.2 μg mL -1 for AML, HCT, and VAL, respectively, being specific (peak purity > 0.999), accurate (bias ofanalyte recoveries <2.0%), and precise (inter-and intra-day variations <2%). It was also robust to small changes inflow rate (±0.05 mL min -1), pH (±0.1 unit) and proportion of MeOH (±3%) in the mobile phase. The method was applied to the assay of AML, HCT, and VAL in tablets of their novel association and formulations containing the HCT-VAL and AML-VAL binary combinations. Copyright © Taylor & Francis Group, LLC.
Fil: Vignaduzzo, Silvana Edit. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Fil: Castellano, Patricia Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Fil: Kaufman, Teodoro Saul. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Materia: EXPERIMENTAL DESIGN
HPLC-DAD
HPLC-UV
RP-HPLC
TRIPLE COMBINATION
VALIDATION
Nivel de accesibilidad: acceso abierto
Condiciones de uso: https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
Institución: Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador: oai:ri.conicet.gov.ar:11336/127120

Acceder

id	CONICETDig_3cc37c62dd1b0795efa6d932392323ab
oai_identifier_str	oai:ri.conicet.gov.ar:11336/127120
network_acronym_str	CONICETDig
repository_id_str	3498
network_name_str	CONICET Digital (CONICET)
spelling	Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associationsVignaduzzo, Silvana EditCastellano, Patricia MargaritaKaufman, Teodoro SaulEXPERIMENTAL DESIGNHPLC-DADHPLC-UVRP-HPLCTRIPLE COMBINATIONVALIDATIONhttps://purl.org/becyt/ford/1.4https://purl.org/becyt/ford/1The novel triple combination between Amlodipine (AML), Hydrochlorothiazide (HCT), and Valsartan (VAL) provides a new option for treating hypertension. The development and validation of an HPLC method for their simultaneous determination in pharmaceutical combinations, employing experimental design strategies, is reported. The drugs were separated on a C18 column at 30° C, using a 38:62 (v/v) mixture of 30 mMphosphate buffer (pH 5.5) and MeOH as mobile phase, delivered at 1.0mLmin -1. Detection was performed at 234 nm. Despite the wide difference in analytes' concentrations, the method showed good linearity (r 2 > 0.995) in the ranges 7.0-13.0 μg mL -1, 17.6-32.8 μg mL -1, and 226.2-420.2 μg mL -1 for AML, HCT, and VAL, respectively, being specific (peak purity > 0.999), accurate (bias ofanalyte recoveries <2.0%), and precise (inter-and intra-day variations <2%). It was also robust to small changes inflow rate (±0.05 mL min -1), pH (±0.1 unit) and proportion of MeOH (±3%) in the mobile phase. The method was applied to the assay of AML, HCT, and VAL in tablets of their novel association and formulations containing the HCT-VAL and AML-VAL binary combinations. Copyright © Taylor & Francis Group, LLC.Fil: Vignaduzzo, Silvana Edit. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Castellano, Patricia Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Kaufman, Teodoro Saul. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaTaylor & Francis2011-11-18info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/127120Vignaduzzo, Silvana Edit; Castellano, Patricia Margarita; Kaufman, Teodoro Saul; Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations; Taylor & Francis; Journal of Liquid Chromatography and Related Technologies; 34; 19; 18-11-2011; 2383-23951082-6076CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/10826076.2011.591020info:eu-repo/semantics/altIdentifier/doi/10.1080/10826076.2011.591020info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:46:41Zoai:ri.conicet.gov.ar:11336/127120instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:46:41.34CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv	Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
title	Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
spellingShingle	Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations Vignaduzzo, Silvana Edit EXPERIMENTAL DESIGN HPLC-DAD HPLC-UV RP-HPLC TRIPLE COMBINATION VALIDATION
title_short	Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
title_full	Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
title_fullStr	Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
title_full_unstemmed	Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
title_sort	Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
dc.creator.none.fl_str_mv	Vignaduzzo, Silvana Edit Castellano, Patricia Margarita Kaufman, Teodoro Saul
author	Vignaduzzo, Silvana Edit
author_facet	Vignaduzzo, Silvana Edit Castellano, Patricia Margarita Kaufman, Teodoro Saul
author_role	author
author2	Castellano, Patricia Margarita Kaufman, Teodoro Saul
author2_role	author author
dc.subject.none.fl_str_mv	EXPERIMENTAL DESIGN HPLC-DAD HPLC-UV RP-HPLC TRIPLE COMBINATION VALIDATION
topic	EXPERIMENTAL DESIGN HPLC-DAD HPLC-UV RP-HPLC TRIPLE COMBINATION VALIDATION
purl_subject.fl_str_mv	https://purl.org/becyt/ford/1.4 https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv	The novel triple combination between Amlodipine (AML), Hydrochlorothiazide (HCT), and Valsartan (VAL) provides a new option for treating hypertension. The development and validation of an HPLC method for their simultaneous determination in pharmaceutical combinations, employing experimental design strategies, is reported. The drugs were separated on a C18 column at 30° C, using a 38:62 (v/v) mixture of 30 mMphosphate buffer (pH 5.5) and MeOH as mobile phase, delivered at 1.0mLmin -1. Detection was performed at 234 nm. Despite the wide difference in analytes' concentrations, the method showed good linearity (r 2 > 0.995) in the ranges 7.0-13.0 μg mL -1, 17.6-32.8 μg mL -1, and 226.2-420.2 μg mL -1 for AML, HCT, and VAL, respectively, being specific (peak purity > 0.999), accurate (bias ofanalyte recoveries <2.0%), and precise (inter-and intra-day variations <2%). It was also robust to small changes inflow rate (±0.05 mL min -1), pH (±0.1 unit) and proportion of MeOH (±3%) in the mobile phase. The method was applied to the assay of AML, HCT, and VAL in tablets of their novel association and formulations containing the HCT-VAL and AML-VAL binary combinations. Copyright © Taylor & Francis Group, LLC. Fil: Vignaduzzo, Silvana Edit. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina Fil: Castellano, Patricia Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina Fil: Kaufman, Teodoro Saul. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
description	The novel triple combination between Amlodipine (AML), Hydrochlorothiazide (HCT), and Valsartan (VAL) provides a new option for treating hypertension. The development and validation of an HPLC method for their simultaneous determination in pharmaceutical combinations, employing experimental design strategies, is reported. The drugs were separated on a C18 column at 30° C, using a 38:62 (v/v) mixture of 30 mMphosphate buffer (pH 5.5) and MeOH as mobile phase, delivered at 1.0mLmin -1. Detection was performed at 234 nm. Despite the wide difference in analytes' concentrations, the method showed good linearity (r 2 > 0.995) in the ranges 7.0-13.0 μg mL -1, 17.6-32.8 μg mL -1, and 226.2-420.2 μg mL -1 for AML, HCT, and VAL, respectively, being specific (peak purity > 0.999), accurate (bias ofanalyte recoveries <2.0%), and precise (inter-and intra-day variations <2%). It was also robust to small changes inflow rate (±0.05 mL min -1), pH (±0.1 unit) and proportion of MeOH (±3%) in the mobile phase. The method was applied to the assay of AML, HCT, and VAL in tablets of their novel association and formulations containing the HCT-VAL and AML-VAL binary combinations. Copyright © Taylor & Francis Group, LLC.
publishDate	2011
dc.date.none.fl_str_mv	2011-11-18
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	http://hdl.handle.net/11336/127120 Vignaduzzo, Silvana Edit; Castellano, Patricia Margarita; Kaufman, Teodoro Saul; Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations; Taylor & Francis; Journal of Liquid Chromatography and Related Technologies; 34; 19; 18-11-2011; 2383-2395 1082-6076 CONICET Digital CONICET
url	http://hdl.handle.net/11336/127120
identifier_str_mv	Vignaduzzo, Silvana Edit; Castellano, Patricia Margarita; Kaufman, Teodoro Saul; Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations; Taylor & Francis; Journal of Liquid Chromatography and Related Technologies; 34; 19; 18-11-2011; 2383-2395 1082-6076 CONICET Digital CONICET
dc.language.none.fl_str_mv	eng
language	eng
dc.relation.none.fl_str_mv	info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/10826076.2011.591020 info:eu-repo/semantics/altIdentifier/doi/10.1080/10826076.2011.591020
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv	openAccess
rights_invalid_str_mv	https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv	application/pdf application/pdf
dc.publisher.none.fl_str_mv	Taylor & Francis
publisher.none.fl_str_mv	Taylor & Francis
dc.source.none.fl_str_mv	reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str	CONICET Digital (CONICET)
collection	CONICET Digital (CONICET)
instname_str	Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv	CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv	dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_	1846083563208835072
score	13.22299

Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and b...

Publicaciones similares